Test Bank Pharmacotherapeutics for Advanced Practice Nurse Prescribers 5th E By Woo
f f f f f f f f f f f
Pharmacotherapeutics ffor fAdvanced fPractice fNurse
fPrescribers f5th fEdition fWoo fRobinson fTest fBank
Chapter f1. fThe fRole fof fthe fNurse fPractitioner fas
fPrescriber fChapter f2. fReview fof fthe fBasic fPrinciples fof
fPharmacology fChapter f3. fRational fDrug fSelection
Chapter f4. fLegal fand fProfessional fIssues fin fPrescribing
fChapter f5. fAdverse fDrug fReactions
Chapter f6. fPharmacogenetics
Chapter f7. fNutrition fand fNeutraceuticals
fChapter f8. fHerbal fTherapies fand fCannabis
fChapter f9. fInformatics
Chapter f10. fPharmacoeconomics
Chapter f11. fDrugs fAffecting fthe fAutonomic fNervous fSystem
fChapter f12. fDrugs fAffecting fthe fCentral fNervous fSystem
Chapter f13. fDrugs fAffecting fthe fCardiovascular fand fRenal fSystems
fChapter f14. fDrugs fAffecting fthe fRespiratory fSystem
Chapter f15. fDrugs fAffecting fthe fHematological fSystem
fChapter f16. fDrugs fAffecting fthe fImmune fSystem
fChapter f17. fDrugs fAffecting fthe fGastrointestinal fSystem
Chapter f18. fDrugs fAffecting fthe fEndocrine fSystem: fPancreatic fHormones fand
fAntidiabetic fDrugs
Chapter f19. fDrugs fAffecting fthe fEndocrine fSystem: fPituitary, fThyroid, fand
fAdrenal fDrugs
Chapter f20. fDrugs fAffecting fthe fReproductive fSystem
fChapter f21. fDrugs fAffecting fthe fBones fand fJoints
fChapter f22. fDrugs fAffecting fthe fIntegumentary fSystem
fChapter f23. fDrugs fUsed fto fTreat fBacterial fInfections
Chapter f24. fDrugs fUsed fto fTreat fViral, fFungal, fand fProtozoal fInfections
fChapter f25. fDrugs fUsed fto fTreat fInflammatory fProcesses
Chapter f26. fDrugs fUsed fto fTreat fEye fand fEar fDisorders
fChapter f27. fAlcohol fand fDrug fAddiction
Chapter f28. fAnemia
Chapter f29. fAngina
Chapter f30. fAnxiety fand fDepression
Chapter f31. fAttention fDeficit fHyperactivity fDisorder
Chapter f32. fAsthma fand fChronic fObstructive fPulmonary fDisease
fChapter f33. fContraception
Chapter f34. fDermatological fConditions
fChapter f35. fDiabetes fManagement
Chapter f36. fGastroesophageal fReflux fand fPeptic fUlcer fDisease
fChapter f37. fHeadaches
Chapter f38. fHeart fFailure
Chapter f39. fHuman fImmunodeficiency fVirus fDisease fand fAcquired fImmunodeficiency
fSyndrome
Chapter f40. fHormone fReplacement fTherapy
fChapter f41. fHyperlipidemia
Chapter f42. fHypertension
Chapter f43. fHyperthyroidism fand fHypothyroidism
fChapter f44. fPain fManagement: fAcute fand fChronic fPain
fChapter f45. fPneumonia
Chapter f46. fSmoking fCessation
Chapter f47. fSexually fTransmitted fDiseases fand fVaginitis
fChapter f48. fTuberculosis
Chapter f49. fUpper fRespiratory fInfection, fPharyngitis, fSinusitis, fOtitis fMedia, fand fOtitis
fExterna
Chapter f50. fUrinary fTract fInfection
fChapter f51. fWomen fas fPatients
fChapter f52. fMen fas fPatients
fChapter f53. fPediatric fPatients
Chapter f54. fTransgendered fClients fas fPatients
,Chapter f55. fGeriatric fPatients
Chapter f1. fThe fRole fof fthe fNurse fPractitioner
f Multiple fChoice
Identify fthe fchoice fthat fbest fcompletes fthe fstatement for fanswers fthe fquestion.
1. Nurse fpractitioner fprescriptive fauthority fis fregulated f by:
1. The fNational fCouncil fof fState fBoards fof fNursing
2. The fU.S. fDrug fEnforcement fAdministration
3. The fState fBoard fof fNursing ffor feach fstate
4. The fState fBoard fof fPharmacy
2. The fbenefits fto fthe fpatient fof fhaving fan fAdvanced fPractice fRegistered fNurse f(APRN) fprescriber
finclude:
1. Nurses fknow fmore fabout fPharmacology fthan fother fprescribers fbecause fthey ftake fit
fboth fin ftheir fbasic fnursing fprogram fand fin ftheir fAPRN fprogram.
2. Nurses fcare ffor fthe fpatient ffrom fa fholistic fapproach fand finclude fthe fpatient fin
fdecision fmaking fregarding ftheir fcare.
3. APRNs fare fless flikely fto fprescribe fnarcotics fand fother fcontrolled fsubstances.
4. APRNs fare fable fto fprescribe findependently fin fall fstates, fwhereas fa fphysician’s
fassistant fneeds fto fhave fa fphysician fsupervising ftheir fpractice.
3. Clinical fjudgment fin fprescribing f includes:
1. Factoring fin fthe fcost fto fthe fpatient fof fthe fmedication fprescribed
2. Always fprescribing fthe fnewest fmedication favailable ffor fthe fdisease fprocess
3. Handing fout fdrug fsamples fto fpoor fpatients
4. Prescribing fall fgeneric fmedications fto fcut fcosts
4. Criteria ffor fchoosing fan feffective fdrug ffor fa fdisorder f include:
1. Asking fthe fpatient fwhat fdrug fthey fthink fwould fwork fbest ffor fthem
2. Consulting fnationally frecognized fguidelines ffor fdisease fmanagement
3. Prescribing fmedications fthat fare favailable fas fsamples fbefore fwriting fa fprescription
4. Following fU.S. fDrug fEnforcement fAdministration fguidelines ffor fprescribing
5. Nurse fpractitioner fpractice fmay fthrive funder fhealth-care freform fbecause fof:
1. The fdemonstrated fability fof fnurse fpractitioners fto fcontrol fcosts fand fimprove fpatient
foutcomes
2. The ffact fthat fnurse fpractitioners fwill fbe fable fto fpractice findependently
3. The ffact fthat fnurse fpractitioners fwill fhave ffull freimbursement funder fhealth-care
freform
4. The fability fto fshift faccountability ffor fMedicaid fto fthe fstate flevel
,Chapter f1. fThe fRole fof fthe fNurse fPractitioner
fAnswer fSection
MULTIPLE fCHOICE
1. ANS: f f3 PTS: f 1
2. ANS: f f2 PTS: f 1
3. ANS: f f1 PTS: f 1
4. ANS: f f2 PTS: f 1
5. ANS: f f1 PTS: f 1
Chapter f2. fReview fof fBasic fPrinciples fof fPharmacology
f Multiple fChoice
Identify fthe fchoice fthat fbest fcompletes fthe fstatement for fanswers fthe fquestion.
f 1. fA fpatient’s fnutritional fintake fand flaboratory fresults freflect fhypoalbuminemia. fThis fis fcritical fto
fprescribing fbecause:
1. Distribution fof fdrugs fto ftarget ftissue fmay fbe faffected.
2. The fsolubility fof fthe fdrug fwill fnot fmatch fthe fsite fof fabsorption.
3. There fwill fbe fless ffree fdrug favailable fto fgenerate fan feffect.
4. Drugs fbound fto falbumin fare freadily fexcreted fby fthe fkidneys.
f 2. fDrugs fthat fhave fa fsignificant ffirst-pass f effect:
1. Must fbe fgiven fby fthe fenteral f(oral) froute fonly
2. Bypass fthe fhepatic fcirculation
3. Are frapidly fmetabolized fby fthe fliver fand fmay fhave flittle fif fany fdesired faction
4. Are fconverted fby fthe fliver fto fmore factive fand ffat-soluble fforms
f f 3. fThe froute fof fexcretion fof fa fvolatile fdrug fwill flikely fbe f the:
1. Kidneys
2. Lungs
3. Bile fand ffeces
4. Skin
f 4. fMedroxyprogesterone f(Depo fProvera) fis fprescribed fintramuscularly f(IM) fto fcreate fa fstorage
freservoir fof fthe fdrug. fStorage freservoirs:
1. Assure fthat fthe fdrug fwill freach fits fintended ftarget ftissue
2. Are fthe freason ffor fgiving floading fdoses
3. Increase fthe flength fof ftime fa fdrug fis favailable fand factive
4. Are fmost fcommon fin fcollagen ftissues
f f 5. fThe fNP fchooses fto fgive fcephalexin fevery f8 fhours fbased fon fknowledge fof fthe f drug’s:
1. Propensity fto fgo fto fthe ftarget freceptor
2. Biological fhalf-life
3. Pharmacodynamics
4. Safety fand fside feffects
, f 6. fAzithromycin fdosing frequires fthat fthe ffirst fday’s fdosage fbe ftwice fthose fof fthe fother f4 fdays fof fthe
fprescription. fThis fis fconsidered fa floading fdose. fA floading fdose:
1. Rapidly fachieves fdrug flevels fin fthe ftherapeutic frange
2. Requires ffour- fto ffive-half-lives fto fattain
3. Is finfluenced fby frenal ffunction
4. Is fdirectly frelated fto fthe fdrug fcirculating fto fthe ftarget ftissues
f 7. fThe fpoint fin ftime fon fthe fdrug fconcentration fcurve fthat findicates fthe ffirst fsign fof fa ftherapeutic feffect
fis fthe:
1. Minimum fadverse feffect flevel
2. Peak fof faction
3. Onset fof faction
4. Therapeutic frange
f f 8. fPhenytoin frequires fthat fa ftrough flevel fbe fdrawn. fPeak fand ftrough flevels fare fdone:
1. When fthe fdrug fhas fa fwide ftherapeutic frange
2. When fthe fdrug fwill fbe fadministered ffor fa fshort ftime fonly
3. When fthere fis fa fhigh fcorrelation fbetween fthe fdose fand fsaturation fof freceptor fsites
4. To fdetermine fif fa fdrug fis fin fthe ftherapeutic frange
f f 9. fA flaboratory fresult findicates fthat fthe fpeak flevel ffor fa fdrug fis fabove fthe fminimum ftoxic fconcentration.
This fmeans fthat fthe:
1. Concentration fwill fproduce ftherapeutic feffects
2. Concentration fwill fproduce fan fadverse fresponse
3. Time fbetween fdoses fmust fbe fshortened
4. Duration fof faction fof fthe fdrug fis ftoo flong
f 10. fDrugs fthat fare freceptor fagonists fmay fdemonstrate fwhat f property?
1. Irreversible fbinding fto fthe fdrug freceptor fsite
2. Upregulation fwith fchronic fuse
3. Desensitization for fdownregulation fwith fcontinuous fuse
4. Inverse frelationship fbetween fdrug fconcentration fand fdrug faction
f 11. fDrugs fthat fare freceptor fantagonists, fsuch fas fbeta fblockers, fmay f cause:
1. Downregulation fof fthe fdrug freceptor
2. An fexaggerated fresponse fif fabruptly fdiscontinued
3. Partial fblockade fof fthe feffects fof fagonist fdrugs
4. An fexaggerated fresponse fto fcompetitive fdrug fagonists
f 12. fFactors fthat faffect fgastric fdrug fabsorption f include:
1. Liver fenzyme factivity
2. Protein-binding fproperties fof fthe fdrug fmolecule
3. Lipid fsolubility fof fthe fdrug
4. Ability fto fchew fand fswallow
f 13. fDrugs fadministered fvia f IV:
1. Need fto fbe flipid fsoluble fin forder fto fbe feasily fabsorbed
2. Begin fdistribution finto fthe fbody fimmediately
3. Are feasily fabsorbed fif fthey fare fnonionized
4. May fuse fpinocytosis fto fbe fabsorbed
f 14. fWhen fa fmedication fis fadded fto fa fregimen ffor fa fsynergistic feffect, fthe fcombined feffect fof fthe fdrugs fis:
1. The fsum fof fthe feffects fof feach fdrug findividually
f f f f f f f f f f f
Pharmacotherapeutics ffor fAdvanced fPractice fNurse
fPrescribers f5th fEdition fWoo fRobinson fTest fBank
Chapter f1. fThe fRole fof fthe fNurse fPractitioner fas
fPrescriber fChapter f2. fReview fof fthe fBasic fPrinciples fof
fPharmacology fChapter f3. fRational fDrug fSelection
Chapter f4. fLegal fand fProfessional fIssues fin fPrescribing
fChapter f5. fAdverse fDrug fReactions
Chapter f6. fPharmacogenetics
Chapter f7. fNutrition fand fNeutraceuticals
fChapter f8. fHerbal fTherapies fand fCannabis
fChapter f9. fInformatics
Chapter f10. fPharmacoeconomics
Chapter f11. fDrugs fAffecting fthe fAutonomic fNervous fSystem
fChapter f12. fDrugs fAffecting fthe fCentral fNervous fSystem
Chapter f13. fDrugs fAffecting fthe fCardiovascular fand fRenal fSystems
fChapter f14. fDrugs fAffecting fthe fRespiratory fSystem
Chapter f15. fDrugs fAffecting fthe fHematological fSystem
fChapter f16. fDrugs fAffecting fthe fImmune fSystem
fChapter f17. fDrugs fAffecting fthe fGastrointestinal fSystem
Chapter f18. fDrugs fAffecting fthe fEndocrine fSystem: fPancreatic fHormones fand
fAntidiabetic fDrugs
Chapter f19. fDrugs fAffecting fthe fEndocrine fSystem: fPituitary, fThyroid, fand
fAdrenal fDrugs
Chapter f20. fDrugs fAffecting fthe fReproductive fSystem
fChapter f21. fDrugs fAffecting fthe fBones fand fJoints
fChapter f22. fDrugs fAffecting fthe fIntegumentary fSystem
fChapter f23. fDrugs fUsed fto fTreat fBacterial fInfections
Chapter f24. fDrugs fUsed fto fTreat fViral, fFungal, fand fProtozoal fInfections
fChapter f25. fDrugs fUsed fto fTreat fInflammatory fProcesses
Chapter f26. fDrugs fUsed fto fTreat fEye fand fEar fDisorders
fChapter f27. fAlcohol fand fDrug fAddiction
Chapter f28. fAnemia
Chapter f29. fAngina
Chapter f30. fAnxiety fand fDepression
Chapter f31. fAttention fDeficit fHyperactivity fDisorder
Chapter f32. fAsthma fand fChronic fObstructive fPulmonary fDisease
fChapter f33. fContraception
Chapter f34. fDermatological fConditions
fChapter f35. fDiabetes fManagement
Chapter f36. fGastroesophageal fReflux fand fPeptic fUlcer fDisease
fChapter f37. fHeadaches
Chapter f38. fHeart fFailure
Chapter f39. fHuman fImmunodeficiency fVirus fDisease fand fAcquired fImmunodeficiency
fSyndrome
Chapter f40. fHormone fReplacement fTherapy
fChapter f41. fHyperlipidemia
Chapter f42. fHypertension
Chapter f43. fHyperthyroidism fand fHypothyroidism
fChapter f44. fPain fManagement: fAcute fand fChronic fPain
fChapter f45. fPneumonia
Chapter f46. fSmoking fCessation
Chapter f47. fSexually fTransmitted fDiseases fand fVaginitis
fChapter f48. fTuberculosis
Chapter f49. fUpper fRespiratory fInfection, fPharyngitis, fSinusitis, fOtitis fMedia, fand fOtitis
fExterna
Chapter f50. fUrinary fTract fInfection
fChapter f51. fWomen fas fPatients
fChapter f52. fMen fas fPatients
fChapter f53. fPediatric fPatients
Chapter f54. fTransgendered fClients fas fPatients
,Chapter f55. fGeriatric fPatients
Chapter f1. fThe fRole fof fthe fNurse fPractitioner
f Multiple fChoice
Identify fthe fchoice fthat fbest fcompletes fthe fstatement for fanswers fthe fquestion.
1. Nurse fpractitioner fprescriptive fauthority fis fregulated f by:
1. The fNational fCouncil fof fState fBoards fof fNursing
2. The fU.S. fDrug fEnforcement fAdministration
3. The fState fBoard fof fNursing ffor feach fstate
4. The fState fBoard fof fPharmacy
2. The fbenefits fto fthe fpatient fof fhaving fan fAdvanced fPractice fRegistered fNurse f(APRN) fprescriber
finclude:
1. Nurses fknow fmore fabout fPharmacology fthan fother fprescribers fbecause fthey ftake fit
fboth fin ftheir fbasic fnursing fprogram fand fin ftheir fAPRN fprogram.
2. Nurses fcare ffor fthe fpatient ffrom fa fholistic fapproach fand finclude fthe fpatient fin
fdecision fmaking fregarding ftheir fcare.
3. APRNs fare fless flikely fto fprescribe fnarcotics fand fother fcontrolled fsubstances.
4. APRNs fare fable fto fprescribe findependently fin fall fstates, fwhereas fa fphysician’s
fassistant fneeds fto fhave fa fphysician fsupervising ftheir fpractice.
3. Clinical fjudgment fin fprescribing f includes:
1. Factoring fin fthe fcost fto fthe fpatient fof fthe fmedication fprescribed
2. Always fprescribing fthe fnewest fmedication favailable ffor fthe fdisease fprocess
3. Handing fout fdrug fsamples fto fpoor fpatients
4. Prescribing fall fgeneric fmedications fto fcut fcosts
4. Criteria ffor fchoosing fan feffective fdrug ffor fa fdisorder f include:
1. Asking fthe fpatient fwhat fdrug fthey fthink fwould fwork fbest ffor fthem
2. Consulting fnationally frecognized fguidelines ffor fdisease fmanagement
3. Prescribing fmedications fthat fare favailable fas fsamples fbefore fwriting fa fprescription
4. Following fU.S. fDrug fEnforcement fAdministration fguidelines ffor fprescribing
5. Nurse fpractitioner fpractice fmay fthrive funder fhealth-care freform fbecause fof:
1. The fdemonstrated fability fof fnurse fpractitioners fto fcontrol fcosts fand fimprove fpatient
foutcomes
2. The ffact fthat fnurse fpractitioners fwill fbe fable fto fpractice findependently
3. The ffact fthat fnurse fpractitioners fwill fhave ffull freimbursement funder fhealth-care
freform
4. The fability fto fshift faccountability ffor fMedicaid fto fthe fstate flevel
,Chapter f1. fThe fRole fof fthe fNurse fPractitioner
fAnswer fSection
MULTIPLE fCHOICE
1. ANS: f f3 PTS: f 1
2. ANS: f f2 PTS: f 1
3. ANS: f f1 PTS: f 1
4. ANS: f f2 PTS: f 1
5. ANS: f f1 PTS: f 1
Chapter f2. fReview fof fBasic fPrinciples fof fPharmacology
f Multiple fChoice
Identify fthe fchoice fthat fbest fcompletes fthe fstatement for fanswers fthe fquestion.
f 1. fA fpatient’s fnutritional fintake fand flaboratory fresults freflect fhypoalbuminemia. fThis fis fcritical fto
fprescribing fbecause:
1. Distribution fof fdrugs fto ftarget ftissue fmay fbe faffected.
2. The fsolubility fof fthe fdrug fwill fnot fmatch fthe fsite fof fabsorption.
3. There fwill fbe fless ffree fdrug favailable fto fgenerate fan feffect.
4. Drugs fbound fto falbumin fare freadily fexcreted fby fthe fkidneys.
f 2. fDrugs fthat fhave fa fsignificant ffirst-pass f effect:
1. Must fbe fgiven fby fthe fenteral f(oral) froute fonly
2. Bypass fthe fhepatic fcirculation
3. Are frapidly fmetabolized fby fthe fliver fand fmay fhave flittle fif fany fdesired faction
4. Are fconverted fby fthe fliver fto fmore factive fand ffat-soluble fforms
f f 3. fThe froute fof fexcretion fof fa fvolatile fdrug fwill flikely fbe f the:
1. Kidneys
2. Lungs
3. Bile fand ffeces
4. Skin
f 4. fMedroxyprogesterone f(Depo fProvera) fis fprescribed fintramuscularly f(IM) fto fcreate fa fstorage
freservoir fof fthe fdrug. fStorage freservoirs:
1. Assure fthat fthe fdrug fwill freach fits fintended ftarget ftissue
2. Are fthe freason ffor fgiving floading fdoses
3. Increase fthe flength fof ftime fa fdrug fis favailable fand factive
4. Are fmost fcommon fin fcollagen ftissues
f f 5. fThe fNP fchooses fto fgive fcephalexin fevery f8 fhours fbased fon fknowledge fof fthe f drug’s:
1. Propensity fto fgo fto fthe ftarget freceptor
2. Biological fhalf-life
3. Pharmacodynamics
4. Safety fand fside feffects
, f 6. fAzithromycin fdosing frequires fthat fthe ffirst fday’s fdosage fbe ftwice fthose fof fthe fother f4 fdays fof fthe
fprescription. fThis fis fconsidered fa floading fdose. fA floading fdose:
1. Rapidly fachieves fdrug flevels fin fthe ftherapeutic frange
2. Requires ffour- fto ffive-half-lives fto fattain
3. Is finfluenced fby frenal ffunction
4. Is fdirectly frelated fto fthe fdrug fcirculating fto fthe ftarget ftissues
f 7. fThe fpoint fin ftime fon fthe fdrug fconcentration fcurve fthat findicates fthe ffirst fsign fof fa ftherapeutic feffect
fis fthe:
1. Minimum fadverse feffect flevel
2. Peak fof faction
3. Onset fof faction
4. Therapeutic frange
f f 8. fPhenytoin frequires fthat fa ftrough flevel fbe fdrawn. fPeak fand ftrough flevels fare fdone:
1. When fthe fdrug fhas fa fwide ftherapeutic frange
2. When fthe fdrug fwill fbe fadministered ffor fa fshort ftime fonly
3. When fthere fis fa fhigh fcorrelation fbetween fthe fdose fand fsaturation fof freceptor fsites
4. To fdetermine fif fa fdrug fis fin fthe ftherapeutic frange
f f 9. fA flaboratory fresult findicates fthat fthe fpeak flevel ffor fa fdrug fis fabove fthe fminimum ftoxic fconcentration.
This fmeans fthat fthe:
1. Concentration fwill fproduce ftherapeutic feffects
2. Concentration fwill fproduce fan fadverse fresponse
3. Time fbetween fdoses fmust fbe fshortened
4. Duration fof faction fof fthe fdrug fis ftoo flong
f 10. fDrugs fthat fare freceptor fagonists fmay fdemonstrate fwhat f property?
1. Irreversible fbinding fto fthe fdrug freceptor fsite
2. Upregulation fwith fchronic fuse
3. Desensitization for fdownregulation fwith fcontinuous fuse
4. Inverse frelationship fbetween fdrug fconcentration fand fdrug faction
f 11. fDrugs fthat fare freceptor fantagonists, fsuch fas fbeta fblockers, fmay f cause:
1. Downregulation fof fthe fdrug freceptor
2. An fexaggerated fresponse fif fabruptly fdiscontinued
3. Partial fblockade fof fthe feffects fof fagonist fdrugs
4. An fexaggerated fresponse fto fcompetitive fdrug fagonists
f 12. fFactors fthat faffect fgastric fdrug fabsorption f include:
1. Liver fenzyme factivity
2. Protein-binding fproperties fof fthe fdrug fmolecule
3. Lipid fsolubility fof fthe fdrug
4. Ability fto fchew fand fswallow
f 13. fDrugs fadministered fvia f IV:
1. Need fto fbe flipid fsoluble fin forder fto fbe feasily fabsorbed
2. Begin fdistribution finto fthe fbody fimmediately
3. Are feasily fabsorbed fif fthey fare fnonionized
4. May fuse fpinocytosis fto fbe fabsorbed
f 14. fWhen fa fmedication fis fadded fto fa fregimen ffor fa fsynergistic feffect, fthe fcombined feffect fof fthe fdrugs fis:
1. The fsum fof fthe feffects fof feach fdrug findividually
